Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Catholic University of the Sacred Heart | OTHER |
| Ospedale Policlinico San Martino | OTHER |
| Azienda Ospedaliera San Paolo | OTHER |
| Ospedale Amedeo di Savoia |
Not provided
Not provided
Not provided
Prospective, randomized study (1: 1), open-label, controlled, phase 3, multicenter, non-profit. The hypothesis of the present study is that bictegravir is associated with a lower incidence and severity of neuropsychiatric symptoms than dolutegravir.
Prospective, randomized study (1: 1), open-label, controlled, phase 3, multicenter, non-profit. The hypothesis of the present study is that bictegravir is associated with a lower incidence and severity of neuropsychiatric symptoms than dolutegravir. The main outcome measure will be a global severity index (GSI) of neuropsychiatric symptoms arising from 10 symptom domains, including somatization, obsessive-compulsiveness, interpersonal sensitivity, depression, anxiety, hostility, phobic anxiety, paranoid ideation, psychoticism. The secondary outcomes are to compare, between arms and during follow up, neuropsychiatric symptoms severity, neurocognitive performance, changes in self-reported symptoms, adherence and HR-QoL, correlation between symptoms (neuropsychiatric and other), drug exposure and HR-QoL, proportion of adverse events, proportion of virological failures and antiretrovirals resistance at virological failure.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Bictegravir/emtricitabine/tenofovir alafenamide | Experimental | Patients with suppressed viral load switching from dolutegravur/lamivudina/abacavir (50/300/600 mg) 1 tablet OD to bictegravir/emtricitabine/tenofovir alafenamide (50/200/25 mg) 1 tablet OD |
|
| Dolutegravir/lamivudine/abacavir | Active Comparator | Patients with suppressed viral load continuing dolutegravir/lamivudine/abacavir (50/300/600 mg) 1 tablet OD |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Bictegravir/emtricitabine/tenofovir alafenamide | Drug | Switch patients from dolutegravir/lamivudine/abacavir to bictegravir/emtricitabine/tenefovir alafenamide to study neuropsychiatric side effects and neurocognitive function |
| Measure | Description | Time Frame |
|---|---|---|
| neuropsychiatric symptoms severity in 3 months | change in neuropsychiatric symptoms severity, using the Symptom Checklist-90-R, 3 months after switching to bictegravir or continuing dolutegravir (on treatment analysis). | 3 months |
| Measure | Description | Time Frame |
|---|---|---|
| neuropsychiatric symptoms severity in 3 and 12 months | change in neuropsychiatric symptoms severity, each of the 10 symptoms analyzed separately using the Symptom Checklist-90-R, 3 and 12 months after switching to bictegravir or dolutegravir (on treatment analysis) | 12 months |
| Mini International Neuropsychiatric Interview Plus subscale for suicide risk |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Barbara Rossetti, PhD | Contact | +393201437658 | barbara.rossetti@ao-siena.toscana.it | |
| Maurizio Zazzi, Prof | Contact | +390577233863 | maurizio.zazzi@unisi.it |
| Name | Affiliation | Role |
|---|---|---|
| Barbara Rossetti, PhD | Azienda Ospedaliera Universitaria Senese | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Barbara Rossetti | Recruiting | Siena | 53100 | Italy |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| C000654125 | bictegravir, emtricitabine, tenofovir alafenamide, drug combination |
| C000631408 | abacavir, dolutegravir, and lamivudine drug combination |
Not provided
Not provided
Not provided
| OTHER |
Prospective, randomized study (1: 1), open-label, controlled, phase 3, multicenter, non-profit
Not provided
Not provided
Not provided
Not provided
|
| Dolutegravir/lamivudine/abacavir | Drug | Continuing dolutegravir/lamivudine/abacavir to study neuropsychiatric side effects and neurocognitive function |
|
|
change in neuropsychiatric symptoms severity, using the Mini International Neuropsychiatric Interview Plus subscale for suicide risk, 3 and 12 months after switching to bictegravir or dolutegravir (on treatment analysis). Suicide risk (five questions, score range 0-33 points) in the last 30 days was classified as low (1-5), moderate (6-9), or high (10). |
| 12 months |
| neurocognitive performance | change in neurocognitive performance, using a comprehensive and validated neuropsychological battery, 12 months after switching to bictegravir or dolutegravir (on treatment analysis). The neurocognitive performance is calculated by averaging the individual deficit scores from each neurocognitive test. Deficit scores for each test were calculated from age-, education-, -adjusted raw scores. | 12 months |
| neurocognitive impairment and neuropsychiatric symptoms | comparison of the inter-arm and intra-arm incidence of neurocognitive impairment (on the basis of Frascati criteria) at 12 months and neuropsychiatric symptoms (using the Symptom Checklist-90-R) at 3 (on treatment analysis) and 12 months (ITT-exposed, using LOCF) | 12 months |
| self-reported symptoms (21 items, 0-5 points for each), adherence (0-100%) and HR-QoL (9 items, 0-5 points for each) | changes in self-reported symptoms, adherence and HR-QoL (using validated questionnaires) during the first year of follow up (ITT-exposed, using LOCF). | 12 months |
| drug exposure | correlation between symptoms (neuropsychiatric and other), drug exposure and HR-QoL during the first year of follow up (ITT-exposed, using LOCF). | 12 months |
| adverse events | proportion of adverse events and serious adverse events and of patients discontinuing due to side effects in both arms | 12 months |
| virological failures | proportion of virological failures and antiretrovirals resistance at virological failure | 12 months |
| Treatment Satisfaction | change in Treatment Satisfaction between arms as per specific questionnaire (TSQM Version 1.4, 15 questions, from 0 to 79 points as maximum) | 12 months |